LTS:0L35 (USA)
Business Description
Sarepta Therapeutics Inc
NAICS : 325412
SIC : 2834
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Compare
Compare
Traded in other countries / regions
S1RP34.Brazil
•
AB3A.Germany
•
0L35.UK
•
SRPT.USA
Description
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.69 | |||||
| Equity-to-Asset | 0.24 | |||||
| Debt-to-Equity | 1.57 | |||||
| Debt-to-EBITDA | -2.87 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.43 | |||||
| Beneish M-Score | -2.2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 23.9 | |||||
| 3-Year EBITDA Growth Rate | 6.5 | |||||
| 3-Year EPS without NRI Growth Rate | 1.9 | |||||
| 3-Year FCF Growth Rate | 4.4 | |||||
| 3-Year Book Growth Rate | -9.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 39.77 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 12-1 Month Momentum % | -0.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.53 | |||||
| Quick Ratio | 4.14 | |||||
| Cash Ratio | 3.53 | |||||
| Days Inventory | 675.01 | |||||
| Days Sales Outstanding | 70.92 | |||||
| Days Payable | 180.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 85.1 | |||||
| Operating Margin % | -52.48 | |||||
| Net Margin % | -60.66 | |||||
| ROE % | -73.09 | |||||
| ROA % | -17.32 | |||||
| ROIC % | -55.38 | |||||
| ROC (Joel Greenblatt) % | -138.58 | |||||
| ROCE % | -17.71 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 11.13 | |||||
| PB Ratio | 13.14 | |||||
| Price-to-Tangible-Book | 13.37 | |||||
| EV-to-EBIT | -19.99 | |||||
| EV-to-EBITDA | -22.07 | |||||
| EV-to-Revenue | 10.49 | |||||
| EV-to-FCF | -25.19 | |||||
| Price-to-Median-PS-Value | 0.36 | |||||
| Price-to-Net-Current-Asset-Value | 48.16 | |||||
| Earnings Yield (Greenblatt) % | -5 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 835.184 | ||
| EPS (TTM) ($) | -5.88 | ||
| Beta | 0.96 | ||
| Volatility % | 11.85 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0.000007 | ||
| 20-Day SMA ($) | 79.95 | ||
| 12-1 Month Momentum % | -0.57 | ||
| 52-Week Range ($) | 77.953 - 80.25 | ||
| Shares Outstanding (Mil) | 87.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sarepta Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||